Amiloride reduces stroke and renal injury in stroke-prone hypertensive rats

American Journal of Hypertension

Volumn 16, Issue 4, 2003, Pages 312-318

  Sepehrdad, Reza ^a   Chander, Praveen N ^a   Oruene, Alafuro ^a   Rosenfeld, Louis ^a   Levine, Seymour ^a   Stier Jr , Charles T ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Amiloride; Blood pressure; Malignant nephrosclerosis; Proteinuria; Stroke

Indexed keywords

AMILORIDE; EPLERENONE; MINERALOCORTICOID RECEPTOR; MINERALOCORTICOID RECEPTOR ANTAGONIST; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; SPIRONOLACTONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; BLOOD PRESSURE MEASUREMENT; BLOOD VESSEL INJURY; BODY WEIGHT; BRAIN TISSUE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRINKING; DRUG MECHANISM; DRUG RECEPTOR BINDING; ELECTROLYTE EXCRETION; HISTOPATHOLOGY; HYPERTENSION; KIDNEY EPITHELIUM; KIDNEY PARENCHYMA; MALE; MEAN ARTERIAL PRESSURE; NEUROPROTECTION; NONHUMAN; PATHOLOGICAL ANATOMY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEINURIA; QUANTITATIVE ASSAY; RAT; SALT INTAKE; SODIUM BLOOD LEVEL; SPONTANEOUSLY HYPERTENSIVE RAT; STATISTICAL SIGNIFICANCE; STROKE; SURVIVAL; SYSTOLIC BLOOD PRESSURE; TELEMETRY; URINARY EXCRETION;

EID: 0037382169     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(03)00006-2     Document Type: Article

References (29)

1. Stier CT Jr, Chander PN, Gutstein WH, Levine S, Itskovitz HD: Therapeutic benefit of captopfil in salt-loaded stroke-prone spontaneously hypertensive rats is independent of hypotensive effect. Am J Hypertens 1991;4:680-687.
2. Stier CT Jr, Mahboubi K, DiPippo VA, Levine S, Chander PN: The antiproteinuric action of enalapfil in stroke-prone spontaneously hypertensive rats is unrelated to alterations in urinary prostaglandins. J Pharmacol Exp Therap 1992;260:1410-1415.
3. Stier CT Jr, Adler LA, Levine S, Chander PN: Stroke prevention by losartan in stroke-prone spontaneously hypertensive rats. J Hypertens 1993;11(Suppl 3):S37-S42.
4. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr: Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998;31:451-458.
5. Rocha R, Stier CT Jr: Pathophysiologic effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab 2001;12:308-314.
6. Fejes-Toth G, Pearce D, Naray-Fejes-Toth A: Subcellular localization of mineralocorticoid receptors in living cells: effects of receptor agonists and antagonists. Proc Natl Acad Sci 1998;95:2973-2978.
7. Funder JW: Aldosterone action. Annu Rev Physiol 1993;55:115-130.
8. Narikiyo T, Kitamura K, Adachi M, Miyoshi T, Iwashita K, Shiraishi N, Nonoguchi H, Chen L-M, Chai KX, Chao J, Tomita K: Regulation of prostasin by aldosterone in the kidney. J Clin Invest 2002;109:401-408.
9. Chen S-Y, Bhargava A, Mastroberardino L, Meijer OC, Wang J, Buse P, Firestone GL, Verrey F Pearce: Epithelial sodium channel regulated by aldosterone-induced protein sgk. Proc Natl Acad Sci 1999;96:2514-2519.
10. + channel. J Biol Chem 1997;272:21075-21083.
11. Pearce D: The role of SGK1 in hormone-regulated sodium transport. Trends Endocrinol Metab 2001;12:341-347.
12. + channels. Steroids 1995;60:114-119.
13. Campbell SE, Janicki JS, Matsubara BB, Weber KT: Myocardial fibrosis in the rat with mineralocorticoid excess. Prevention of scarring by amiloride. Am J Hypertens 1993;6:487-495.
14. Benos DJ, Stanton BA: Functional domains within the degenerin/ epithelial sodium channel (Deg/ENaC) superfamily of ion channels. J Physiol 1999;520:631-644.
15. Litchfield WR, Anderson BF, Weiss RJ, Lifton RP, Dluhy RG: Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism. Hypertension 1998;31:445-450.
16. Jeunemaitre X, Bassilana F, Persu A, Dumont C, Champigny G, Lazdunski M, Corvol P, Barbry P: Genotype-phenotype analysis of a newly discovered family with Liddle's syndrome. J Hypertens 1997;15:1091-1100.
17. Multicenter Diuretic Cooperative Study Group: Multiclinic comparison of amiloride, hydrochlorothiazide, and hydrochlorothiazide plus amiloride in essential hypertension. Arch Intern Med 1981;141:482-486.
18. Barrett RJ, Buckenheimer TJ, McGuirk BA, Kau ST: Comparative cardiovascular effects of loop-acting thiazide-type and potassium-sparing diuretics in spontaneously hypertensive rats. Meth Find Exptl Clin Pharmacol 1987;9:67-87.
19. Barret RJ, Kau ST: Myocardial and vascular actions of amiloride in spontaneously hypertensive rats. J Pharmacol Exp Ther 1986;239:365-374.
20. Haddy FJ, Pamnani MB: Pharmacologic agents for the in vivo detection of vascular sodium transport defects in hypertension. Life Sci 1987;41:2685-2696.
21. +-ATPase inhibitor regulating precapillary vessel tone. J Cardiovasc Pharm 1984;6(Suppl 2):S439-S456.
22. Gomez-Sanchez EP: What is the role of the central nervous system in mineralocorticoid hypertension? Am J Hypertens 1991;4:374-381.
23. Gomez-Sanchez EP, Gomez-Sanchez CE: Effect of central amiloride infusion on mineralocorticoid hypertension. Am J Physiol 1994;267:E754-E758.
24. Pratt JH, Eckert GJ, Newman S, Ambrosius WT: Blood pressure responses to small doses of amiloride and spironolactone in normotensive subjects. Hypertension 2001;38:1124-1129.
25. Tobian L, Lange J, Ulm K, Wold L, Iwai J: Potassium reduces cerebral hemorrhage and death rate in hypertensive rats, even when blood pressure is not lowered. Hypertension 1985;7:I-110-I-114.
26. + feeding in stroke-prone hypertensive rats. Hypertension 1990;15:318-326.
27. Golestaneh N, Klein C, Valamanesh F, Suarez G, Agarwal MK, Mirshahi M: Mineralocorticoid receptor-mediated signaling regulates the ion gated sodium channel in vascular endothelial cells and requires an intact cytoskeleton. Biochem Biophys Res Comm 2001;280:1300-1306.
28. Vigne P, Champigny G, Marsault R, Barbry P, Frelin C, Lazdunski M: A new type of amiloride-sensitive cationic channel in endothelial cells of brain microvessels. J Biol Chem 1989;264:7663-7668.
29. McCarty MF: Endothelial membrane potential regulates production of both nitric oxide and superoxide - a fundamental determinant of vascular health. Medical Hypotheses 1999;53:277-289.